Boye et al. [177] suggest that CD147 could be used in the selection of stage III patients for adjuvant therapy for colorectal cancer, and Yang et al. [98] showed that CD147 expression is associated with poor overall survival in patients with glioblastoma and suggest that CD147 may be used to detect treatment response in glioblastoma patients. The gene discussed is BSG; the disease is glioblastoma.